Hostname: page-component-77f85d65b8-grvzd Total loading time: 0 Render date: 2026-03-26T19:57:31.340Z Has data issue: false hasContentIssue false
  • English
  • Français

Management of Neurosurgical Instruments and Patients Exposed to Creutzfeldt-Jakob Disease

Published online by Cambridge University Press:  02 January 2015

Ermias D. Belay ,
Jennifer Blase ,
Lynne M. Sehulster ,
Ryan A. Maddox  and
Lawrence B. Schonberger
Ermias D. Belay*
Affiliation:
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Jennifer Blase
Affiliation:
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Lynne M. Sehulster
Affiliation:
Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Ryan A. Maddox
Affiliation:
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
Lawrence B. Schonberger
Affiliation:
Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia
*
1600 Clifton Road, Mailstop A-30, Atlanta, GA 30333 (ebelay@cdc.gov)
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To summarize the approaches used to manage exposure of patients to inadequately sterilized neurosurgical instruments contaminated as a result of Creutzfeldt-Jakob disease (CJD).

Methods.

Information on past CJD exposure incidents reported to the Centers for Disease Control and Prevention (CDC) was aggregated and summarized. In addition, inactivation studies were reviewed, and data from selected publications were provided for reference.

Results.

Nineteen incidents of patient exposure to potentially CJD-contaminated instruments were reported to the CDC, including 17 that involved intracranial procedures and 2 that involved ophthalmologic procedures. In more than 50% of incidents, the neurosurgical procedures were performed for diagnostic work up of the index patients. At least 12 of the hospitals had multiple neurosurgical sets, and the CJD-contaminated instruments could not be identified in 11 of 19 hospitals. In 12 of 15 hospitals with neurosurgical incidents, a decision was made to notify patients of their potential exposure.

Conclusions.

Neurosurgical instruments used for treatment of patients with suspected or diagnosed CJD or patients whose diagnosis is unclear should be promptly identified and sterilized using recommended CJD decontamination protocols. Inability to trace instruments complicates appropriate management of exposure incidents. The feasibility of instituting instrument tracking procedures should be considered.

Information

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 34 , Issue 12 , December 2013 , pp. 1272 - 1280
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Belay, ED, Schonberger, LB. The public health impact of prion diseases. Annu Rev Public Health 2005;26:191–212.Google Scholar
2.Prusiner, SB. Novel proteinaceous infectious particles cause scrapie. Science 1982;216:136–144.Google Scholar
3.Holman, RC, Belay, ED, Christensen, KY, et al. Human prion diseases in the United States. PLoS ONE 2010;5: e8521.Google Scholar
4.Brown, P, Brandel, JP, Sato, T, et al. Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 2012;18:901–907.CrossRefGoogle ScholarPubMed
5.Belay, ED, Schonberger, LB, Brown, P, et al. Disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol 2010;31:1304–1306.Google Scholar
6.World Health Organization (WHO). WHO infection control guidelines for transmissible spongiform encephalopathies: report of a WHO consultation, Geneva, Switzerland, 2326 March, 1999. http://www.who.int/csr/resources/publications/bse/whocdscsraph2003.pdf. Accessed August 13, 2013.Google Scholar
7.Rutala, WA, Weber, DJ. Guideline for disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol 2010;31:107–117.CrossRefGoogle ScholarPubMed
8.Taylor, DM. Resistance of transmissible spongiform encephalopathy agents to decontamination. Contrib Microbiol 2004:136–145.Google Scholar
9.Centers for Disease Control and Prevention. Questions and answers: Creutzfeldt-Jakob disease infection control practices. http://www.cdc.gov/ncidod/dvrd/cjd/qa_cjd_infection_control.htm. Accessed August 12, 2013.Google Scholar
10.Taylor, DM, Fernie, K, McConnell, I. Inactivation of the 22A strain of scrapie agent by autoclaving in sodium hydroxide. Vet Microbiol 1997;58:87–91.Google Scholar
11.Taylor, DM, Fernie, K, McConnell, I, Steele, PJ. Observations on thermostable subpopulations of the unconventional agents that cause transmissible degenerative encephalopathies. Vet Microbiol 1998;64:33–38.Google Scholar
12.Taylor, DM, Fernie, K, McConnell, I, Steele, PJ. Survival of scrapie agent after exposure to sodium dodecyl sulphate and heat. Vet Microbiol 1999;67:13–16.Google Scholar
13.Fichet, G, Comoy, E, Dehen, C, et al. Investigations of a prion infectivity assay to evaluate methods of decontamination. J Microbiol Methods 2007;70:511–518.Google Scholar
14.Fichet, G, Comoy, E, Duval, C, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004;364:521–526.Google Scholar
15.Yan, ZX, Stitz, L, Heeg, P, Pfaff, E, Roth, K. Infectivity of prion protein bound to stainless steel wires: a model for testing decontamination procedures for transmissible spongiform encephalopathies. Infect Control and Hosp Epidemiol 2004;25:280–283.Google Scholar
16.Jackson, GS, McKintosh, E, Flechsig, E, et al. An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol 2005;86:869–878.Google Scholar
17.Fernie, K, Steele, PJ, Taylor, DM, Somerville, RA. Comparative studies on the thermostability of five strains of transmissible spongiform encephalopathy agent. Biotechnol Appl Biochem 2007;47:175–183.CrossRefGoogle ScholarPubMed
18.Lehmann, S, Pastore, M, Rogez-Kreuz, C, et al. New hospital disinfection processes for both conventional and prion infectious agents compatible with thermosensitive medical equipment. J Hosp Infect 2009;72:342–350.Google Scholar
19.Rogez-Kreuz, C, Yousfi, R, Eng, M, et al. Inactivation of animal and human prions by hydrogen peroxide gas plasma sterilization. Infect Control Hosp Epidemiol 2009;30:769–777.Google Scholar
20.Edgeworth, JA, Sicilia, A, Linehan, J, Brandner, S, Jackson, GS, Collinge, J. A standardized comparison of commercially available prion decontamination reagents using the standard steel-binding assay. JGen Virol 2011;92:718–726.Google Scholar
21.Giles, K, Glidden, DV, Beckwith, R, et al. Resistance of bovine spongiform encephalopathy (BSE) prions to inactivation. PLoS Pathog 2008;4:e1000206.Google Scholar
22.Peretz, D, Supattapone, S, Giles, K, et al. Inactivation of prions by acidic sodium dodecyl sulfate. J Virol 2006;80:322–331.Google Scholar
23.Will, RG, Matthews, WB. Evidence for case-to-case transmission of Creutzfeldt-Jakob disease. Neurol Neurosurg Psych 1982;45:235–238.Google Scholar
24.Bernoulli, C, Siegfried, J, Baumgartner, G, et al. Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977;1:478–479.Google Scholar
25.Stricof, RL, Lillquist, PP, Thomas, N, Belay, ED, Schönberger, LB, Morse, DL. An investigation of potential neurosurgical transmission of Creutzfeldt-Jakob disease: challenges and lessons learned. Infect Control Hosp Epidemiol 2006;27:302–304.Google Scholar
26.Ward, HJ, Everington, D, Croes, EA, et al. Sporadic Creutzfeldt-Jakob disease and surgery: a case-control study using community controls. Neurology 2002;59:543–548.Google Scholar
27.van Duijn, CM, Delasnerie-Laupretre, N, Masullo, C, et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU) collaborative study group of Creutzfeldt-Jakob disease (CJD). Lancet 1998;351:1081–1085.Google Scholar
28.Hamaguchi, T, Noguchi-Shinohara, M, Nozaki, I, et al. Medical procedures and risk for sporadic Creutzfeldt-Jakob disease, Japan, 1999-2008. Emerg Infect Dis 2009;15:265–271.Google Scholar
29. Sentinel Event Alert, issue 20: exposure to Creutzfeldt-Jakob disease, June 1, 2001. http://www.jointcommission.org/sentinel_event_alert_issue_20_exposure_to_creutzfeldt-jakob _disease/. Accessed August 12, 2013.Google Scholar
30.Belay, ED, Holman, RC, Schonberger, LB. Creutzfeldt-Jakob disease surveillance and diagnosis. Clin Infect Dis 2005;41:834–836.Google Scholar
31.Stoeck, K, Sanchez-Juan, P, Gawinecka, J, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. Brain 2012;135:3051–3061.Google Scholar
32.McGuire, LI, Peden, AH, Orru, CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2012;72:278–285.Google Scholar
33.Maddox, RA, Belay, ED, Curns, AT, et al. Creutzfeldt-Jakob disease in recipients of corneal transplants. Cornea 2008;27:851–854.Google Scholar
34.UK Department of Health. Management of possible exposure to CJD through medical procedures: framework document. 2011. http://webarchive.nationalarchives.gov.uk/20060715141954/ http://hpa.org.uk/infections/topics_az/cjd/framework_Aug%202005.pdf. Accessed August 12, 2013.Google Scholar
35.Rutala, WA, Weber, DJ, Reply to Belay et al. Infect Control Hosp Epidemiol 2010;31:1306–1308.Google Scholar
36.World Health Organization (WHO). WHO tables on tissue infectivity distribution in transmissible spongiform encephalopathies: updated 2010. Geneva, Switzerland: World Health Organization, 2010. http://www.who.int/bloodproducts/tablestissueinfectivity.pdf. Accessed August 12, 2013.Google Scholar
37.Brown, SA, Merritt, K. Use of containment pans and lids for autoclaving caustic solutions. Am J Infect Control 2003;31:257–260.Google Scholar
38.Brown, SA, Merritt, K, Woods, TO, Busick, DN. Effects on instruments of the World Health Organization: recommended protocols for decontamination after possible exposure to transmissible spongiform encephalopathy-contaminated tissue. J Biomed Mater Res B Appl Biomater 2005;72B:186–190.Google Scholar